Alcobra blasted by a PhIII flop for ADHD drug as its options dwindle
You can turn out the lights at Alcobra. The party is over, and it ended badly.
This morning the Israeli biotech $ADHD revealed that its Phase III study of MDX flopped. The drug failed to distinguish itself from a placebo, and the company will now start considering the strategic options left to it as a result.
There won’t be many options to choose from. MDX was its only drug in the clinic and in a conference call with investors execs told analysts that they are ending work on the program.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.